• 全站搜索
  • 研究院活动
  • 独家专访
  • 学术会议
  • 专家教授
  • 科研基金
  • 学习资源
 至
【指南】2006 NACB检验医学实践指南:母胎健康风险评估
11122014/09/04 收藏

文章类型:指南原文

语言:英文

中文标题:2006 NACB检验医学实践指南:母胎健康风险评估

英文标题:The National Academy of Clinical Biochemistry  Laboratory Medicine Practice Guidelines  Maternal-Fetal Risk Assessment and Reference Values in Pregnancy  Published Guidelines

制定者:美国临床生化科学院(NACB,The National Academy of Clinical Biochemistry)

制定日期:2006.1.1

 

摘要:The emergence of new technologies and markers often occurs at a much higher velocity that can be captured,
validated, put into accepted practice, and reviewed for inclusion in these guidelines. For example, in the prenatal
screening area, there is considerable discussion of both second trimester markers such as ITA and Adam 12, but
they are not yet in routine practice, in contrast to Inhibin A. The issue of first-trimester screening and nuchal
translucency is still being widely discussed. One potential reference is the recent paper by David Wright and Ian
Bradbury (BJOG 2005;112:80–83). Commercialization of new markers such as soluble vascular endothelial
growth factors and placental growth factors for preeclampsia are also gathering some momentum.More manufacturers have committed to and invested in resources for the development of age-related reference
ranges. Even though informed consent requirements have become more daunting, as this goes to press there are
several initiatives and studies underway to develop enhanced neonatal and pediatric ranges. Finally, when this guideline was begun, tandem MS/MS was being performed in limited settings. With every year that has passed, more applications and capabilities for assaying not only novel, but routine, biomarkers have come into common practice.

 

 

本文下载链接见下方。

 

文档下载
2006 NACB检验医学实践指南:母胎健康风险评估 所需积分:2

分享至:
  • 0 条评论
  • 如有账号请登录
合生元营养与护理研究院 2014 版权所有 粤ICP备14071153号    网站声明
Copyright © 2014 Powered by biostime